

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Dasatinib, nilotinib and standard-dose imatinib for the first line treatment of chronic myeloid leukaemia (incl part-review of TA 70)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (post-referral)

Version of matrix of consultees and commentators reviewed:					
Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
	The provisional matrix uses an incorrect name for one of the professional groups identified as a consultee. We suggest that: "The British Committee for Standardisation in Haematology" is changed to: "British Committee for Standards in Haematology"	Novartis Pharmaceuticals		Actioned.	